vs
Digimarc CORP（DMRC）与Fortress Biotech, Inc.（FBIO）财务数据对比。点击上方公司名可切换其他公司
Fortress Biotech, Inc.的季度营收约是Digimarc CORP的1.8倍（$16.1M vs $8.9M），Fortress Biotech, Inc.净利率更高（-24.5% vs -47.2%，领先22.7%），Fortress Biotech, Inc.同比增速更快（6.3% vs 2.9%），过去两年Fortress Biotech, Inc.的营收复合增速更高（11.0% vs -5.3%）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
堡垒生物科技（Fortress Biotech）是一家生物制药企业，核心业务为收购、开发并商业化创新医药与生物技术产品。公司由医学博士林赛·A·罗森瓦尔德担任首席执行官，包括绝大多数子公司在内，公司总部均设于佛罗里达州贝港群岛。
DMRC vs FBIO — 直观对比
营收规模更大
FBIO
是对方的1.8倍
$8.9M
营收增速更快
FBIO
高出3.4%
2.9%
净利率更高
FBIO
高出22.7%
-47.2%
两年增速更快
FBIO
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $16.1M |
| 净利润 | $-4.2M | $-3.9M |
| 毛利率 | 63.5% | 66.1% |
| 营业利润率 | -48.2% | -28.8% |
| 净利率 | -47.2% | -24.5% |
| 营收同比 | 2.9% | 6.3% |
| 净利润同比 | 51.4% | 41.8% |
| 每股收益（稀释后） | $-0.18 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCFBIO
| Q4 25 | $8.9M | $16.1M | ||
| Q3 25 | $7.6M | $17.6M | ||
| Q2 25 | $8.0M | $16.4M | ||
| Q1 25 | $9.4M | $13.1M | ||
| Q4 24 | $8.7M | $15.1M | ||
| Q3 24 | $9.4M | $14.6M | ||
| Q2 24 | $10.4M | $14.9M | ||
| Q1 24 | $9.9M | $13.0M |
净利润DMRCFBIO
| Q4 25 | $-4.2M | $-3.9M | ||
| Q3 25 | $-8.2M | $5.8M | ||
| Q2 25 | $-8.2M | $15.5M | ||
| Q1 25 | $-11.7M | $-10.6M | ||
| Q4 24 | $-8.6M | $-6.8M | ||
| Q3 24 | $-10.8M | $-12.9M | ||
| Q2 24 | $-9.3M | $-10.9M | ||
| Q1 24 | $-10.3M | $-15.4M |
毛利率DMRCFBIO
| Q4 25 | 63.5% | 66.1% | ||
| Q3 25 | 58.3% | 67.4% | ||
| Q2 25 | 58.8% | 69.9% | ||
| Q1 25 | 65.0% | 63.5% | ||
| Q4 24 | 60.8% | 69.1% | ||
| Q3 24 | 62.4% | 69.4% | ||
| Q2 24 | 66.1% | 61.6% | ||
| Q1 24 | 62.5% | 53.9% |
营业利润率DMRCFBIO
| Q4 25 | -48.2% | -28.8% | ||
| Q3 25 | -109.7% | -38.6% | ||
| Q2 25 | -105.2% | -222.2% | ||
| Q1 25 | -128.9% | -169.9% | ||
| Q4 24 | -105.1% | -158.3% | ||
| Q3 24 | -120.4% | -151.0% | ||
| Q2 24 | -96.2% | -186.5% | ||
| Q1 24 | -109.2% | -280.6% |
净利率DMRCFBIO
| Q4 25 | -47.2% | -24.5% | ||
| Q3 25 | -106.9% | 33.2% | ||
| Q2 25 | -102.6% | 94.4% | ||
| Q1 25 | -125.2% | -80.6% | ||
| Q4 24 | -99.9% | -44.7% | ||
| Q3 24 | -113.9% | -88.0% | ||
| Q2 24 | -89.3% | -73.5% | ||
| Q1 24 | -104.0% | -118.3% |
每股收益（稀释后）DMRCFBIO
| Q4 25 | $-0.18 | $-0.15 | ||
| Q3 25 | $-0.38 | $0.11 | ||
| Q2 25 | $-0.38 | $0.45 | ||
| Q1 25 | $-0.55 | $-0.48 | ||
| Q4 24 | $-0.40 | $-0.16 | ||
| Q3 24 | $-0.50 | $-0.76 | ||
| Q2 24 | $-0.43 | $-0.73 | ||
| Q1 24 | $-0.50 | $-1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $79.4M |
| 总债务越低越好 | — | $52.4M |
| 股东权益账面价值 | $40.2M | $49.9M |
| 总资产 | $53.0M | $185.5M |
| 负债/权益比越低杠杆越低 | — | 1.05× |
8季度趋势，按日历期对齐
现金及短期投资DMRCFBIO
| Q4 25 | $12.9M | $79.4M | ||
| Q3 25 | $12.6M | $86.2M | ||
| Q2 25 | $16.1M | $74.4M | ||
| Q1 25 | $21.6M | $91.3M | ||
| Q4 24 | $28.7M | $57.3M | ||
| Q3 24 | $33.7M | $58.9M | ||
| Q2 24 | $41.5M | $76.2M | ||
| Q1 24 | $48.9M | $83.8M |
总债务DMRCFBIO
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $47.8M | ||
| Q2 25 | — | $50.0M | ||
| Q1 25 | — | $56.4M | ||
| Q4 24 | — | $58.0M | ||
| Q3 24 | — | $52.5M | ||
| Q2 24 | — | $67.0M | ||
| Q1 24 | — | $61.4M |
股东权益DMRCFBIO
| Q4 25 | $40.2M | $49.9M | ||
| Q3 25 | $41.4M | $55.9M | ||
| Q2 25 | $46.5M | $43.9M | ||
| Q1 25 | $50.0M | $22.3M | ||
| Q4 24 | $61.4M | $22.7M | ||
| Q3 24 | $70.2M | $21.2M | ||
| Q2 24 | $77.2M | $17.9M | ||
| Q1 24 | $84.5M | $23.0M |
总资产DMRCFBIO
| Q4 25 | $53.0M | $185.5M | ||
| Q3 25 | $55.4M | $181.4M | ||
| Q2 25 | $60.7M | $159.9M | ||
| Q1 25 | $66.5M | $178.1M | ||
| Q4 24 | $75.8M | $144.2M | ||
| Q3 24 | $85.0M | $127.1M | ||
| Q2 24 | $93.4M | $145.7M | ||
| Q1 24 | $99.7M | $164.6M |
负债/权益比DMRCFBIO
| Q4 25 | — | 1.05× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 2.53× | ||
| Q4 24 | — | 2.55× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 3.75× | ||
| Q1 24 | — | 2.67× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-12.5M |
| 自由现金流经营现金流 - 资本支出 | $895.0K | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | — |
8季度趋势，按日历期对齐
经营现金流DMRCFBIO
| Q4 25 | $991.0K | $-12.5M | ||
| Q3 25 | $-2.6M | $-6.1M | ||
| Q2 25 | $-4.7M | $-27.6M | ||
| Q1 25 | $-5.5M | $-19.6M | ||
| Q4 24 | $-4.2M | $-12.9M | ||
| Q3 24 | $-7.1M | $-20.1M | ||
| Q2 24 | $-6.8M | $-21.8M | ||
| Q1 24 | $-8.4M | $-25.4M |
自由现金流DMRCFBIO
| Q4 25 | $895.0K | — | ||
| Q3 25 | $-2.8M | — | ||
| Q2 25 | $-4.9M | — | ||
| Q1 25 | $-5.5M | — | ||
| Q4 24 | $-4.2M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $-8.5M | — |
自由现金流率DMRCFBIO
| Q4 25 | 10.0% | — | ||
| Q3 25 | -36.9% | — | ||
| Q2 25 | -61.0% | — | ||
| Q1 25 | -59.1% | — | ||
| Q4 24 | -49.1% | — | ||
| Q3 24 | -75.7% | — | ||
| Q2 24 | -66.1% | — | ||
| Q1 24 | -85.8% | — |
资本支出强度DMRCFBIO
| Q4 25 | 1.1% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | 0.0% | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.1% | — |
现金转化率DMRCFBIO
| Q4 25 | — | — | ||
| Q3 25 | — | -1.04× | ||
| Q2 25 | — | -1.78× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
FBIO
暂无分部数据
